December 27, 2021
Daiichi Sankyo said on December 23 that its HER3 directed antibody drug conjugate (ADC) patritumab deruxtecan obtained Breakthrough Therapy designation from the US FDA for the treatment of certain patients with EGFR-mutated non-small cell lung cancer (NSCLC). The status was...read more